Wealth Enhancement Advisory Services LLC Purchases 339 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Wealth Enhancement Advisory Services LLC boosted its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 2.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 16,685 shares of the company’s stock after acquiring an additional 339 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Mirum Pharmaceuticals were worth $752,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. GAMMA Investing LLC increased its stake in shares of Mirum Pharmaceuticals by 4,555.0% in the 1st quarter. GAMMA Investing LLC now owns 5,586 shares of the company’s stock valued at $252,000 after purchasing an additional 5,466 shares during the last quarter. SG Americas Securities LLC grew its position in Mirum Pharmaceuticals by 174.9% in the first quarter. SG Americas Securities LLC now owns 19,182 shares of the company’s stock valued at $864,000 after acquiring an additional 12,204 shares during the last quarter. MPM Bioimpact LLC raised its stake in Mirum Pharmaceuticals by 19.7% during the fourth quarter. MPM Bioimpact LLC now owns 589,579 shares of the company’s stock worth $24,379,000 after acquiring an additional 96,856 shares in the last quarter. AlphaQuest LLC lifted its holdings in shares of Mirum Pharmaceuticals by 969.6% in the fourth quarter. AlphaQuest LLC now owns 1,829 shares of the company’s stock worth $76,000 after acquiring an additional 1,658 shares during the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of Mirum Pharmaceuticals in the 4th quarter valued at approximately $277,000.

Analyst Ratings Changes

Several brokerages recently commented on MIRM. Raymond James Financial reissued a “strong-buy” rating on shares of Mirum Pharmaceuticals in a research note on Tuesday, May 13th. HC Wainwright reiterated a “buy” rating and issued a $73.00 price target on shares of Mirum Pharmaceuticals in a research note on Monday, May 19th. Wall Street Zen upgraded Mirum Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, June 28th. Finally, JMP Securities increased their target price on Mirum Pharmaceuticals from $74.00 to $76.00 and gave the company a “market outperform” rating in a research report on Friday, May 9th. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $65.50.

Mirum Pharmaceuticals Price Performance

Shares of MIRM opened at $49.93 on Friday. The business has a 50-day moving average of $46.27 and a 200-day moving average of $45.44. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.22 and a quick ratio of 3.04. The company has a market capitalization of $2.47 billion, a price-to-earnings ratio of -31.01 and a beta of 0.97. Mirum Pharmaceuticals, Inc. has a 1 year low of $33.64 and a 1 year high of $54.23.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.05. Mirum Pharmaceuticals had a negative net margin of 20.39% and a negative return on equity of 33.63%. The firm had revenue of $111.59 million during the quarter, compared to analyst estimates of $98.47 million. During the same quarter last year, the business earned ($0.54) EPS. The company’s revenue was up 61.2% compared to the same quarter last year. As a group, equities research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

Insiders Place Their Bets

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 564 shares of the company’s stock in a transaction on Wednesday, July 2nd. The shares were sold at an average price of $48.25, for a total transaction of $27,213.00. Following the sale, the senior vice president owned 2,903 shares of the company’s stock, valued at approximately $140,069.75. This represents a 16.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 14.36% of the stock is owned by corporate insiders.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.